Implications for sarcomere-targeted treatment of cardiomyopathies. Myosin inhibitors have been proposed as a therapeutic strategy to curb the excessive contractility and impaired relaxation seen in Hypertrophic Cardiomyopathy (HCM). The gene discussed is MYH14; the disease is hypertrophic cardiomyopathy.